Fulton Bank N.A. grew its stake in shares of Danaher Co. (NYSE:DHR – Free Report) by 2.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,516 shares of the conglomerate’s stock after acquiring an additional 280 shares during the quarter. Fulton Bank N.A.’s holdings in Danaher were worth $2,414,000 at the end of the most recent quarter.
Several other large investors have also modified their holdings of DHR. Benjamin Edwards Inc. grew its stake in Danaher by 1.8% in the second quarter. Benjamin Edwards Inc. now owns 2,153 shares of the conglomerate’s stock valued at $538,000 after purchasing an additional 38 shares in the last quarter. Wedge Capital Management L L P NC grew its stake in shares of Danaher by 3.2% in the 3rd quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock valued at $342,000 after buying an additional 38 shares in the last quarter. Certified Advisory Corp increased its holdings in Danaher by 4.5% in the second quarter. Certified Advisory Corp now owns 926 shares of the conglomerate’s stock worth $231,000 after buying an additional 40 shares during the last quarter. Meridian Financial Partners LLC raised its position in Danaher by 4.4% during the third quarter. Meridian Financial Partners LLC now owns 957 shares of the conglomerate’s stock valued at $266,000 after acquiring an additional 40 shares in the last quarter. Finally, Kovack Advisors Inc. lifted its stake in Danaher by 3.4% in the third quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock valued at $346,000 after acquiring an additional 41 shares during the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.
Danaher Price Performance
NYSE DHR traded down $1.24 during trading on Wednesday, reaching $237.86. 1,052,025 shares of the company traded hands, compared to its average volume of 2,561,800. Danaher Co. has a 1-year low of $222.53 and a 1-year high of $281.70. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The stock’s 50 day moving average price is $236.17 and its two-hundred day moving average price is $254.11. The company has a market cap of $171.80 billion, a price-to-earnings ratio of 45.39, a P/E/G ratio of 4.33 and a beta of 0.83.
Danaher Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.45%. The ex-dividend date is Friday, December 27th. Danaher’s dividend payout ratio is currently 20.61%.
Wall Street Analysts Forecast Growth
DHR has been the subject of a number of recent research reports. Evercore ISI upped their price objective on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Robert W. Baird cut their target price on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Raymond James lowered their price target on Danaher from $310.00 to $300.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. KeyCorp boosted their price objective on Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. Finally, Bank of America raised Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price target on the stock in a research report on Friday, December 13th. Six analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and an average target price of $286.80.
View Our Latest Stock Report on Danaher
Danaher Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Stories
- Five stocks we like better than Danaher
- Best Aerospace Stocks Investing
- Moderna Shares Spike on H5N1 News—What’s Next for Investors?
- What is MarketRank™? How to Use it
- Nebius Group (NBIS): A Small-Cap Backed by NVIDIA
- Short Selling – The Pros and Cons
- Natural Gas Demand to Surge: Top 3 Stocks and ETFs to Consider
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.